Evidence map›Paper›PMID 37402594›Full record

ArticleBMJ open diabetes research & care2023

Diabetic retinopathy in African-Americans with end-stage kidney disease: a cross-sectional study on prevalence and impact on quality of life.

Michelle Egeolu, Ramoncito L Caleon, Exaucee Manishimwe, Zohyra E Zabala, Bobak Moazzami, Amany Gerges, Ghazala D O'Keefe, Jose Navarrete, Rodolfo J Galindo, Rozalina Grubina McCoy and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open diabetes research & care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Michelle EgeoluDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Ramoncito L CaleonDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Exaucee ManishimweDepartment of Biostatistics, Emory University Atlanta, Atlanta, Georgia, USA.
Zohyra E ZabalaDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0003-4208-6087
Bobak MoazzamiDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Amany GergesDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Ghazala D O'KeefeDepartment of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA.
Jose NavarreteDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Rodolfo J GalindoDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Rozalina Grubina McCoyDivision of Endocrinology, Department of Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID 0000-0002-2289-3183
Priyathama VellankiDepartent of Medicine, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-6544-015X
Limin PengDepartent of Medicine, Emory University, Atlanta, Georgia, USA.
Guillermo E UmpierrezDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA geumpie@emory.edu.ORCID 0000-0002-3252-5026
Emory University · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe prevalence, severity, and quality of life (QoL) impact of diabetic retinopathy (DR) among African-Americans (AAs) with end-stage kidney disease (ESKD) undergoing dialysis are unknown. RESEARCH DESIGN AND

methodsA cross-sectional study was conducted on 93 AA adults with diabetes and ESKD. The diagnosis of DR was based on a review of medical records and/or a positive photograph with a portable hand-held device reviewed by both artificial intelligence software and a retinal specialist. QoL, physical disability social determinants of health (SDoHs) were assessed by standardized questionnaires.

resultsThe prevalence of DR was 75%, with 33% of participants having mild, 9.6% moderate and 57.4% severe DR. A total of 43% had normal visual acuity; 45% had moderate visual impairment; and 12% had severe visual impairment. We found a high burden of disease, multiple SDoH challenges, and low QoL and general health among patients with ESKD. The presence of DR had no significant impact on physical health and QoL compared with participants without DR.

conclusionsDR is present in 75% of AA patients with diabetes and ESKD on haemodialysis. ESKD has a significant burden on general health and QoL; however, DR has a minor additional impact on the overall physical health and QoL in people with ESKD.

Indexed as

Diabetes MellitusDiabetic RetinopathyKidney Failure, ChronicQuality of LifeAdultArtificial IntelligenceBlack or African AmericanCross-Sectional StudiesHumansPrevalenceRetrospective StudiesVision DisordersDiabetes ComplicationsDialysisQuality of LifeRetinopathy

Identifiers

PMID37402594
PMCPMC10335493
OpenAlexW4383106615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.